SG11201406129QA - Protease-regulated antibodies - Google Patents

Protease-regulated antibodies

Info

Publication number
SG11201406129QA
SG11201406129QA SG11201406129QA SG11201406129QA SG11201406129QA SG 11201406129Q A SG11201406129Q A SG 11201406129QA SG 11201406129Q A SG11201406129Q A SG 11201406129QA SG 11201406129Q A SG11201406129Q A SG 11201406129QA SG 11201406129Q A SG11201406129Q A SG 11201406129QA
Authority
SG
Singapore
Prior art keywords
protease
regulated antibodies
antibodies
regulated
Prior art date
Application number
SG11201406129QA
Inventor
Zhuozhi Wang
Ruth Winter
John Murphy
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SG11201406129QA publication Critical patent/SG11201406129QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
SG11201406129QA 2012-03-30 2013-03-14 Protease-regulated antibodies SG11201406129QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261617837P 2012-03-30 2012-03-30
PCT/US2013/031363 WO2013148248A1 (en) 2012-03-30 2013-03-14 Protease-regulated antibodies

Publications (1)

Publication Number Publication Date
SG11201406129QA true SG11201406129QA (en) 2014-10-30

Family

ID=49261048

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406129QA SG11201406129QA (en) 2012-03-30 2013-03-14 Protease-regulated antibodies

Country Status (16)

Country Link
US (2) US9975962B2 (en)
EP (1) EP2841082A4 (en)
JP (2) JP6283017B2 (en)
KR (1) KR20150030639A (en)
CN (2) CN104185474B (en)
AU (1) AU2013240279A1 (en)
BR (1) BR112014024373A2 (en)
CA (1) CA2868789A1 (en)
HK (1) HK1204571A1 (en)
IL (1) IL234848A0 (en)
MX (1) MX2014011781A (en)
RU (1) RU2014143639A (en)
SG (1) SG11201406129QA (en)
TW (1) TW201402605A (en)
WO (1) WO2013148248A1 (en)
ZA (1) ZA201407897B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014024373A2 (en) 2012-03-30 2017-08-08 Bayer Healthcare Llc protease-regulated antibodies
ES2657304T3 (en) * 2013-03-15 2018-03-02 Bayer Healthcare Llc Anti-TFPI antibody variants with differential binding over the pH range to improve pharmacokinetics
SG10201710727UA (en) 2013-05-28 2018-02-27 Dcb Usa Llc Antibody locker for the inactivation of protein drug
CN106687482B (en) 2014-09-17 2022-01-25 诺和诺德股份有限公司 Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
EP4279128A3 (en) * 2015-02-25 2024-02-28 Mogam Institute for Biomedical Research Novel antibody binding to tfpi and composition comprising the same
KR101997241B1 (en) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. Trispecific binding proteins and methods of use
MY195443A (en) 2015-08-19 2023-01-21 Pfizer Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
BR112018073739A2 (en) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. single domain serum albumin binding protein
JP7042467B2 (en) 2016-05-20 2022-03-28 ハープーン セラピューティクス，インク． Single-chain variable fragment CD3 binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102275008B1 (en) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. prostate specific membrane antigen binding protein
MX2019006045A (en) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Psma targeting trispecific proteins and methods of use.
CN110177875B (en) 2016-11-28 2023-11-28 中外制药株式会社 Polypeptides comprising an antigen binding domain and a transport moiety
MX2019005947A (en) * 2016-11-28 2019-08-26 Chugai Pharmaceutical Co Ltd Ligand-binding molecule having adjustable ligand binding activity.
NZ753324A (en) 2016-12-09 2022-02-25 Seagen Inc Bivalent antibodies masked by coiled coils
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3621648A4 (en) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CN111065924A (en) * 2017-05-23 2020-04-24 日内瓦大学 β -2-glycoprotein 1-derived peptides and their use for treating antiphospholipid syndrome
US11136403B2 (en) 2017-10-13 2021-10-05 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
EP3694871A4 (en) 2017-10-13 2021-11-10 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
TWI818934B (en) * 2017-11-28 2023-10-21 日商中外製藥股份有限公司 Ligand-binding molecules with adjustable ligand-binding activity
EP3794038A4 (en) * 2018-05-14 2022-02-16 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
JP7425049B2 (en) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． DLL3 binding protein and method of use
EP4106806A1 (en) 2020-02-21 2022-12-28 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JP2005506073A (en) 2001-10-19 2005-03-03 ザイモジェネティクス，インコーポレイティド Dimerized growth factors and materials and methods for producing the same
CA2573656A1 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
EP2178914A2 (en) * 2007-08-15 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
CN101925612A (en) 2007-11-27 2010-12-22 维文蒂阿生物技术公司 At antibody of the epi-position of the relevant NFKBIB variant of cancer and uses thereof
UA112050C2 (en) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI)
SI3345615T1 (en) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2012001087A1 (en) * 2010-06-30 2012-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
LT2694544T (en) * 2011-04-01 2019-04-25 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
BR112014024373A2 (en) 2012-03-30 2017-08-08 Bayer Healthcare Llc protease-regulated antibodies
CN103509115B (en) * 2012-06-21 2016-03-23 中国科学院上海生命科学研究院 Human cystatin C nano antibody and application thereof
CN104177496B (en) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 Hinge region modification body of human IgG2 antibody

Also Published As

Publication number Publication date
JP2015514085A (en) 2015-05-18
CN104185474B (en) 2017-08-25
WO2013148248A1 (en) 2013-10-03
HK1204571A1 (en) 2015-11-27
CN107266574A (en) 2017-10-20
IL234848A0 (en) 2014-12-31
RU2014143639A (en) 2016-05-27
MX2014011781A (en) 2014-11-26
EP2841082A1 (en) 2015-03-04
BR112014024373A2 (en) 2017-08-08
JP6283017B2 (en) 2018-02-21
AU2013240279A1 (en) 2014-10-16
EP2841082A4 (en) 2015-12-30
ZA201407897B (en) 2016-05-25
CN104185474A (en) 2014-12-03
US9975962B2 (en) 2018-05-22
JP2018064579A (en) 2018-04-26
KR20150030639A (en) 2015-03-20
US20180251570A1 (en) 2018-09-06
US20150064169A1 (en) 2015-03-05
CA2868789A1 (en) 2013-10-03
TW201402605A (en) 2014-01-16

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti-il-23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2930240A4 (en) Anti-folr1 antibody
EP2844290A4 (en) Novel antibodies
ZA201407316B (en) Anti-fgfr2 antibody
EP2832855A4 (en) Novel anti-siglec-15 antibody
EP2826790A4 (en) Gremlin-1 antibody
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HUE041552T2 (en) Anti-phospholipase d4 antibody
PL2935330T3 (en) Anti-notch3 antibodies
EP2804876A4 (en) Novel antibodies
GB201220242D0 (en) Antibody
EP2848633A4 (en) Anti-cxadr antibody
EP2811018A4 (en) ANTI-sAPPß ANTIBODY
IL235188A0 (en) Anti-pdgf-c antibodies
GB201209584D0 (en) Modified antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations